SShortSingh.
Back to feed

Many Americans are not taking GLP-1 drugs as prescribed due to cost and access barriers

0
·4 views

A report indicates that millions of Americans are not using their GLP-1 medications the way they were prescribed. Cost and access barriers are the main reasons, pushing some patients to modify their dosing or schedule. Others are turning to unapproved versions of the drugs as a cheaper alternative. The findings highlight the gap between prescribed treatment and actual patient use. The source is Ars Technica.

Read the full story at Ars Technica

This is an AI-generated summary. ShortSingh links to the original source for the complete article.

Discussion (0)

Log in to join the discussion and vote.

Log in

Related stories

0
TechnologyArs Technica ·

FAA orders third nationwide ground stop in its history

The Federal Aviation Administration has halted flights across the United States in a rare nationwide ground stop, only the third such action in the agency's history. The order was issued while the FAA works to identify and fix the problem it is troubleshooting. Officials have not indicated how long the suspension could last, and it may continue for some time. The agency's response is focused on diagnosing the underlying issue before flights resume.

0
TechnologyBBC Tech ·

Jensen Huang scandal puts Singapore's chip hub status under scrutiny

A scandal involving Nvidia chief executive Jensen Huang has drawn attention to Singapore's role as a major semiconductor hub. The case has also highlighted concerns that the city-state's business-friendly environment may be exploited for alleged illicit trade in chips. The episode poses a dilemma for Singapore, which has long promoted itself as an open and attractive base for technology firms. Officials now face pressure to balance that reputation with tighter scrutiny of trade flows.

0
TechnologyTechCrunch ·

Huang's exit leaves a funding gap for AI startups, investors and founders warn

Nvidia invested tens of billions of dollars into AI startups during Jensen Huang's tenure as its leader. With Huang no longer at the helm, founders and venture capitalists say they expect that backing to shrink. Many anticipate smaller investment checks and lower company valuations as a result. The concern reflects how heavily the AI startup ecosystem has relied on Nvidia's capital and influence.